Proscia and UCSF Partnering to Deliver AI Apps to Improve Cancer Diagnosis

Proscia and UCSF Partnering to Deliver AI Apps to Improve Cancer Diagnosis
Proscia and the University of California San Francisco (UCSF) are partnering to use artificial intelligence (AI) to improve the accuracy and speed of cancer diagnoses, starting with prostate cancer. The collaboration will seek to validate the use of computational applications for pathology subspecialties such as prostate cancer, the second-leading cause of cancer deaths among U.S. males, with 191,930 new cases expected this year, according to the American Cancer Society. For more than a century, cancer diagnoses have relied on the microscopic study of tissue biopsies. A steady decrease in the number of pathologists has made the manual practice unable to keep up with the rising number of cancer cases, AI software company Proscia said in a press release. In prostate cancer, the excessive number of slides examined per case, complicated reporting requirements, and qualitative grading system frequently result in delayed diagnoses, additional tests, and less confidence in treatment plans. Using digital pathology for primary diagnoses can spur quality and efficiency improvements in the process, Proscia said. The company will use volumes of diverse, digitized data collected by UCSF, an early adopter of digital patholo
Subscribe or to access all post and page content.